|  | Finding the right patients for a particular clinical trial involves precision, timeliness and is one of the most important hurdles to successful clinical development. Learn more about early indicators of efficacy and more from a free white paper by TD2. |
Featured Story | By Nick Paul Taylor Sanofi is paying Biond Biologics $125 million upfront for global rights to a novel immune checkpoint inhibitor. The agreement gives Sanofi a near-clinical anti-ILT2 monoclonal antibody designed to turn the innate and adaptive immune systems against tumors. read more |
| |
|---|
|
 | Thank you to Catalent for sponsoring this year's JPM 2021 coverage. |
Top Stories By Amirah Al Idrus This year's virtual J.P. Morgan Healthcare Conference could be a "reset" that changes the trajectory of the meeting and its attendant events. Biopharma executives and their colleagues in communications and PR weighed in on what that means for 2021 and beyond. read more By Nick Paul Taylor Boehringer Ingelheim has partnered with Enara Bio to discover novel shared antigens for its growing cancer vaccine and bispecific activities. The agreement positions Boehringer to access novel “dark antigens” discovered by Enara. read more By Ben Adams This time last year, the life science world descended into San Francisco for the 2020 J. P. Morgan healthcare conference, doing the normal things like blowing a whole year’s budget in one day for a hotel room, shaking hands, doing deals and, if you’re like us, asking questions. read more By Nick Paul Taylor Pfizer has made the first investments through its $500 million Pfizer Breakthrough Growth Initiative (PBGI). Homology Medicines received the biggest piece of the first tranche of PBGI funding, landing $60 million to support its work on treatments for rare genetic diseases. read more By Amirah Al Idrus Move over, gene editing: There’s a new kid on the block. Tessera Therapeutics is pioneering “gene writing,” a kind of genetic medicine it hopes will surmount the limitations of gene editing and gene therapy—and investors have bet more than $230 million on the approach. read more By Amirah Al Idrus Verve Therapeutics debuted nearly two years ago with $58.5 million and a goal to bring one-and-done gene editing treatments to heart disease. Now, the company is marching toward the clinic with a treatment for a genetic form of high cholesterol. The treatment, VERVE-101, is a base editor, meaning it doesn’t cut DNA like CRISPR gene editing systems. read more By Ben Adams The story of a top pharma exec leaving the industry and delving into biotech has always been a fascinating one, but Olema’s new chief, Sean Bohen, M.D., Ph.D., took on the challenge amid the worst pandemic in more than a century. read more By Conor Hale Following its $8 billion pitch last year to acquire Grail and its upcoming multi-tumor blood test, Illumina is planning a deeper dive into cancer genomics with a slew of new biopharma development partnerships. read more By Carly Helfand As JPM goes virtual, there are a few things I definitely won’t miss—at all—about the experience, and most of them have to do with its longtime host venue, the Westin St. Francis. read more By Angus Liu Novartis is way late to the PD-1/L1 game, and, after its own project flunked a late-stage study, the Swiss pharma figures it needs an external candidate as belt and braces. So it picked BeiGene’s PD-1 inhibitor tislelizumab, previously partnered with cancer heavyweight Celgene until its merger with Opdivo developer Bristol Myers Squibb. read more By Ben Adams,Conor Hale Welcome to Day 2 of the annual J. P. Morgan healthcare conference. Here's your need to know, as Sanofi as it again with a second deal in as many days, Novartis talks about the positives of the pandemic on its processes and Boehringer turns to the dark side. read more Resources Sponsored By: Polpharma Biologics Innovative cell lines and early process development are critical to generate a high producing cell lines alongside a USP strategy to meet high quality standards. Sponsored By: Blue Matter Biopharma companies in rare diseases: How to maximize the odds of success by becoming a valued member of the unique “rare disease ecosystem.” Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: GenScript A significant number of new treatments have been approved so far, but some manufacturing and regulatory guidelines pose challenges for advanced therapies, leading to poor production yields. Sponsored by: Catalent Cell and gene therapies hold the promise to offer novel therapeutic avenues for individuals facing serious medical conditions, but bringing them through the clinical trial process introduces a level of supply chain risk and complexity. Sponsored by: AllianceRx Walgreens Prime Gene and cell therapy are shifting paradigms for manufacturers, patients, healthcare providers and pharmacies. We invite you to learn more by reading Gene and Cell Therapy: A New Age of Medicine. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Metabolon Learn six ways metabolomics provides greater confidence, higher success rates and complements the work of your in-house teams for your drug development pipeline. Sponsored by: Covance Download the whitepaper to learn how your safety organization can implement automation technologies to enable process and cost efficiencies, improve resource allocation and ensure compliance and quality. Sponsored By: BBK Worldwide The BBK Worldwide Study Voices 2020 survey gives voice to the healthcare consumer in the wake of COVID-19 and reveals important insights for clinical trial enrollment and engagement. Sponsored by: Premier Research Browse the latest learnings and insights from our clinical development professionals. Sponsored by: Rousselot This infographic describes the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments. Sponsored by: Aldevron Gene and cell therapy organizations are asked to balance the need for rapid clinical progression and stringent quality expectations throughout development. In this document, Aldevron provides an in-depth look at preparing for plasmid manufacturing based on our years of experience. Sponsored By: Outer Edge Technology A sound Cloud Strategy provides the flexibility and tools businesses need to quickly adapt and operate securely in an ever-changing remote work environment. Learn how your company can cost-effectively empower its employees to be productive and secure while working remotely. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools. Sponsored by: Catalent This eBook provides insights on key approaches and considerations for preparing your drug development program for long-term success. Sponsored by: Catalent In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site. Sponsored by: Outer Edge Technology Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now! Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
.jpg/0e01fd1dac8bfa20ff05882786b885f2)
.jpg)
